

# Attracting Life Science Investments in Europe<sup>1</sup>

Fourth Edition 2023

**Life science investments create value: they contribute to health improvement, they create a strong knowledge base, they create high quality jobs, and enhance manufacturing capacity and exports, which in turn generate more economic value. Strong life sciences are an asset for Europe and being a leader in this field will have direct impact on the European citizens' health and will contribute to excellent research.**

**The 2023 report uses 22 indicators for life science investments to assess 22 countries' strengths, weaknesses, and investment profiles:**

- Provides a basis for open debate and constructive discussions with stakeholders and policymakers interested to attract life science investments in their country
- Benchmarks Europe against the US and China in the area of life science attractiveness and investments

## Key Observations:

- It is possible for individual countries to create a distinct profile for life science investments, even within a very competitive environment
- Europe lost global life science leadership to the US and China with the latter investing more and showing faster growth
- Europe's life science and healthcare sectors are fragmented, and the continent is not fully taking advantage of its size potential as a region
- Research funds are lower than in the US, less concentrated in areas of excellence, with insufficient sustainability of research funding in areas of excellence

## Key Recommendations:

- European countries and the EU should have a **stronger long-term vision** on how life science ecosystem should develop. They need a **concerted, collaborative and sustained policy effort** to shape their life science ecosystem, connecting political stability, education, research investments, sustainability, private research, venture capital, and innovation-friendly regulations.
- To achieve this, focused public funding in education and research at both EU and national levels is crucial to prevent inefficiencies caused by fragmentation or resource disparities.



The report is an initiative of the BioMed Alliance, EuropaBio, and Johnson & Johnson. Fourth Edition Ref 'Attracting Life Science Investments in Europe' →

<sup>1</sup><https://www.europabio.org/wp-content/uploads/2023/10/Life-Science-Attractiveness-2023-October-22-Final.pdf>